Taiwan has never felt more significant. Long acknowledged for its extraordinary semiconductor prowess and its efficient National Health Insurance system, Taiwan’s life sciences industry has received less attention, but things are changing fast. This is not due to any single development, but the convergence of several long-building forces. Semiconductor experience is being leveraged across the…
Country Reports
Hong Kong — Asia’s premier financial hub and the indispensable gateway between mainland China and global markets — has defied its sceptics and staged one of the most dramatic comebacks in recent memory. After enduring sluggish GDP growth, depressed stock market valuations, and a painful economic transition between 2021 and 2024, the city has roared…
The United States remains the undisputed global engine of scientific discovery and commercialization, accounting for approximately 40 percent of global pharmaceutical revenues. Supported by an annual public research budget exceeding USD 45 billion through the NIH, the US ecosystem is anchored by world-class hubs in Massachusetts, California, and New Jersey. However, this dominance is being…
Legal & Regulatory
The Pharma Legal Handbook: Serbia answers essential questions about the legal and regulatory environment for pharmaceuticals in Serbia. It is a must-have for any company operating in the country or looking to enter the market. Prepared in association with BDK Advokati, a leading Serbian law firm, it should answer any questions linked to regulation, pricing,…
The Pharma Legal Handbook: Asia Growth & Transition Market answers essential questions about the legal and regulatory environment for pharmaceuticals in Estonia, Latvia and Lithuania. It is a must-have for any company operating in Estonia, Latvia and Lithuania or looking to enter these markets. Prepared in association with TEGOS, a leading Baltic law firm, it…
The Pharma Legal Handbook: Market Access & HTA Romania is a comprehensive country-specific market access and health technology assessment (HTA) guide, developed in collaboration with Mușat & Asociații, one of the leading corporate law firms in Romania.
InFocus
For decades, the Middle East carried some of the world’s highest rates of inherited genetic disease, and almost none of the research data needed to treat it. That equation has flipped, fast. Saudi Arabia, the UAE, and Qatar have spent the past decade building sovereign, population-scale genome programs, backed by real capital and paired with…
InFocus: Rare Disease Clinical Development in Hong Kong explores how the city is positioning itself as a globally relevant centre for orphan drug development, drawing on strong clinical infrastructure, accelerated regulatory pathways, and a growing population genomic database. With rare disease therapies now accounting for 35 percent of the global R&D pipeline and over 50…
China’s biotechnology sector has never been harder to ignore. Chinese-origin programmes now account for half of all large-cap pharma licensing deals with upfronts above USD 50 million — a share that has risen from under five percent just five years ago — and the deal activity shows no sign of slowing. In the first quarter…
InFigures
Taiwan has never felt more significant. Long acknowledged for its extraordinary semiconductor prowess and its efficient National Health Insurance system, Taiwan’s life sciences industry has received less attention, but things are changing fast. This is not due to any single development, but the convergence of several long-building forces. Semiconductor experience is being leveraged across the…
Hong Kong — Asia’s premier financial hub and the indispensable gateway between mainland China and global markets — has defied its sceptics and staged one of the most dramatic comebacks in recent memory. After enduring sluggish GDP growth, depressed stock market valuations, and a painful economic transition between 2021 and 2024, the city has roared…
The United States remains the undisputed global engine of scientific discovery and commercialization, accounting for approximately 40 percent of global pharmaceutical revenues. Supported by an annual public research budget exceeding USD 45 billion through the NIH, the US ecosystem is anchored by world-class hubs in Massachusetts, California, and New Jersey. However, this dominance is being…
